BA
LCTX icon

BlackRock Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-35,662
Closed -$89K – 3779
2016
Q1 		$89K Sell
35,662
-11,420
-24% -$25.5K ﹤0.01% 2970
2015
Q4 		$155K Buy
+47,082
New +$141K ﹤0.01% 2710

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock Advisors's LCTX Position: Q4 2016 in Review

BlackRock Advisors increased its Lineage Cell Therapeutics (LCTX) stake by 6.3% in Q4 2016, buying an estimated $7.45K and bringing the position to 41,078 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

BlackRock Advisors first reported a position in LCTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $498K in Q1 2014. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • BlackRock Advisors held 41,078 shares of Lineage Cell Therapeutics worth $130K as of Q4 2016.
  • BlackRock Advisors bought 2,427 Lineage Cell Therapeutics shares in Q4 2016, an estimated $7.45K.
  • Lineage Cell Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2911 holding.
  • BlackRock Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Lineage Cell Therapeutics position peaked at $498K in Q1 2014.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.